BioCryst Pharmaceuticals, Inc. (BCRX)
9.67
+0.12
(+1.26%)
USD |
NASDAQ |
Aug 24, 16:00
9.77
+0.10
(+1.03%)
After-Hours: 20:00
BioCryst Pharmaceuticals Shareholders Equity (Quarterly) : -454.29M for June 30, 2026
Shareholders Equity (Quarterly) Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Shareholders Equity (Quarterly) Data
| Date | Value |
|---|---|
| June 30, 2026 | -454.29M |
| March 31, 2026 | -553.84M |
| December 31, 2025 | -119.15M |
| September 30, 2025 | -387.89M |
| June 30, 2025 | -421.59M |
| March 31, 2025 | -451.93M |
| December 31, 2024 | -475.93M |
| September 30, 2024 | -468.56M |
| June 30, 2024 | -475.61M |
| March 31, 2024 | -476.17M |
| December 31, 2023 | -455.53M |
| September 30, 2023 | -410.99M |
| June 30, 2023 | -388.71M |
| March 31, 2023 | -328.29M |
| December 31, 2022 | -294.60M |
| September 30, 2022 | -242.66M |
| June 30, 2022 | -213.23M |
| March 31, 2022 | -164.22M |
| December 31, 2021 | -106.99M |
| September 30, 2021 | -147.04M |
| June 30, 2021 | -106.08M |
| March 31, 2021 | -74.99M |
| December 31, 2020 | -19.26M |
| September 30, 2020 | 33.64M |
| June 30, 2020 | 76.51M |
| Date | Value |
|---|---|
| March 31, 2020 | 3.648M |
| December 31, 2019 | 38.25M |
| September 30, 2019 | -41.25M |
| June 30, 2019 | -9.193M |
| March 31, 2019 | 22.51M |
| December 31, 2018 | 49.24M |
| September 30, 2018 | 72.87M |
| June 30, 2018 | 46.18M |
| March 31, 2018 | 62.05M |
| December 31, 2017 | 83.77M |
| September 30, 2017 | 100.63M |
| June 30, 2017 | 24.08M |
| March 31, 2017 | 38.53M |
| December 31, 2016 | 1.578M |
| September 30, 2016 | 3.993M |
| June 30, 2016 | 13.39M |
| March 31, 2016 | 27.80M |
| December 31, 2015 | 47.72M |
| September 30, 2015 | 64.04M |
| June 30, 2015 | 76.09M |
| March 31, 2015 | 64.37M |
| December 31, 2014 | 75.64M |
| September 30, 2014 | 83.45M |
| June 30, 2014 | 90.09M |
| March 31, 2014 | -5.723M |
Shareholders' Equity Definition
Represents the value of Shareholders' Equity as of the close of the report date, belonging to both Preferred and Common Equity Shareholders.
Shareholders Equity (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Shareholders Equity (Quarterly) Benchmarks
| Amgen, Inc. | 11.69B |
| Vertex Pharmaceuticals, Inc. | 20.25B |
| Agenus, Inc. | -199.08M |
| Anika Therapeutics, Inc. | 137.28M |
| Imunon, Inc. | 4.189M |
Shareholders Equity (Quarterly) Related Metrics
| Total Assets (Quarterly) | 557.85M |
| Total Liabilities (Quarterly) | 1.012B |
| Debt to Equity Ratio | -1.842 |
| Current Ratio | 2.321 |
| Net Debt Paydown Yield | -0.06% |